Tag: InspireMD
InspireMD presents positive 30-day follow-up results from C-GUARDIANS clinical trial
InspireMD recently presented 30-day results from the C-GUARDIANS US investigational device exemption (IDE) clinical trial evaluating its CGuard embolic prevention stent (EPS) system for...
Vascular News’ top 10 most popular stories of March 2022
A review of intraoperative adverse events in patients treated with fenestrated and branched endovascular aneurysm repair, meta-analysis findings on peripheral arterial disease symptoms in...
InspireMD announces the inclusion of its CGuard carotid stent in CREST-2...
InspireMD has announced that its CGuard embolic prevention stent system (EPS) will be included as a device option for stenting in CREST-2 (Carotid revascularisation...
SIBERIA trial: Positive one-month results for embolic prevention system
InspireMD has announced positive interim results from the SIBERIA trial, an investigator-initiated study of the CGuard embolic prevention system (EPS). The data were presented...
Regulatory and reimbursement approval of CGuard EPS in Australia
CGuard Embolic Prevention System (EPS) (InspireMD) has been granted regulatory approval by the Therapeutic Goods Administration (part of the Australian Government’s Department of Health)...
Expanded two-year follow-up results from the PARADIGM clinical study using CGuard...
Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24-month follow-up results from the...
InspireMD announces expansion of its distribution network for CGuard EPS
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...
